StockTok Wire

StockTok’s daily headlines and financial news driving the broader market

Madrigal Reveals Rezdiffra™ (resmetirom) Significantly Enhances Noninvasive Tests and Reduces Portal Hypertension Risk in Compensated MASH Cirrhosis Patients: New Clinical Data

Madrigal’s Rezdiffra™ (resmetirom) improves noninvasive tests, lowers portal hypertension risk in MASH Cirrhosis patients: New data.

Madrigal Reveals Rezdiffra™ (resmetirom) Significantly Enhances Noninvasive Tests and Reduces Portal Hypertension Risk in Compensated MASH Cirrhosis Patients: New Clinical Data Read More »